AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12742477 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus with full-dose Prograf
Number of subjects: 0
Study 12742477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 10388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control policy
Number of subjects: 2
Study 10388978 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood glucose control policy
Number of subjects: 2
Study 10388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight BP control policy
Number of subjects: 2
Study 10388978 — intervention group
Group type: COMPARATOR
Intervention: Less tight BP control policy
Number of subjects: 2
Study 10388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with macrovascular complications
Number of subjects: 2
Study 10388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with microvascular complications
Number of subjects: 2
Study 10388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with two or more hypoglycemic episodes
Number of subjects: 2
Study 8840366 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)‐α treatment
Number of subjects: 15
Study 8840366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 1796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg body weight once daily for 5 days
Number of subjects: 31
Study 1796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg body weight once daily for 3 days
Number of subjects: 31
Study 1796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (both regimens)
Number of subjects: 31
Study 1796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (single daily doses)
Number of subjects: 31
Study 6404290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 200 mg
Number of subjects: 6
Study 6404290 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 6
Study 31675943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nutrition intervention including food vouchers, egg-based nutritious snacks, micronutrient powder, child feeding counselling, WASH, behaviour change communication
Number of subjects: 0
Study 31675943 — intervention group
Group type: COMPARATOR
Intervention: Routine health messages provided by the government
Number of subjects: 0
Study 30080284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) plus mycophenolate mofetil (MMF)
Number of subjects: 117
Study 30080284 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) plus mycophenolate mofetil (MMF)
Number of subjects: 117
Study 27569229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position group (Group L, n = 34)
Number of subjects: 72
Study 27569229 — intervention group
Group type: COMPARATOR
Intervention: Supine position group (Group S, n = 38)
Number of subjects: 72
Study 24530169 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga plus usual GP care
Number of subjects: 133
Study 22526914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 68
Study 22526914 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC)
Number of subjects: 68
Study 19127264 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) diagnosis of malignancy
Number of subjects: 491
Study 19127264 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) detection of malignant lesions
Number of subjects: 491
Study 19127264 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) detection of individuals affected with malignancy
Number of subjects: 491
Study 17559458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental lignocaine (2% lignocaine solution with adrenaline 1 : 80 000)
Number of subjects: 86
Study 17559458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 86
Study 15507811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic or physiotherapy treatment
Number of subjects: 314
Study 11803613 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) > or = 30 (Group I)
Number of subjects: 427
Study 11803613 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI) < 30 (Group II)
Number of subjects: 427
Study 9632126 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmol Mg daily for 3 months
Number of subjects: 50
Study 9632126 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 3 months
Number of subjects: 50
Study 9632126 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma Mg concentration
Number of subjects: 50
Study 7870633 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of anti-hypertensive therapy
Number of subjects: 60
Study 7870633 — intervention group
Group type: COMPARATOR
Intervention: Continuation of anti-hypertensive therapy
Number of subjects: 60
Study 2846455 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiembolism stockings (AES)
Number of subjects: 12
Study 2846455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 12
Study 2846455 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study 30514264 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment self-defense (ESD) training, 12 hours over 6 weeks with refreshers
Number of subjects: 6644
Study 30514264 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment self-defense (ESD) training
Number of subjects: 6644
Study 30514264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6644
Study 27740565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HFS)
Number of subjects: 0
Study 24759826 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 938
Study 24759826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 938
Study 24759826 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) based ART
Number of subjects: 938
Study 24759826 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine-based ART
Number of subjects: 938
Study 22691892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day for six months
Number of subjects: 0
Study 22691892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20216533 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (oral amoxicillin 1500 mg/day, tetracycline 1500 mg/day, metronidazole 750 mg/day)
Number of subjects: 210
Study 20216533 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 210
Study 18845665 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine T-stenting with sirolimus-eluting stents (SES) in both branches
Number of subjects: 202
Study 18845665 — intervention group
Group type: COMPARATOR
Intervention: Provisional T-stenting with SES placement in the main branch followed by kissing-balloon angioplasty and provisional SES placement in the side branch
Number of subjects: 202
Study 16085582 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-based intracoronary Q measurement using a proprietary guidewire device during adenosine-induced hyperemic flow (140 mug/kg/min for 7 min)
Number of subjects: 0
Study 16085582 — intervention group
Group type: EXPERIMENTAL
Intervention: APV-derived CFVR
Number of subjects: 0
Study 16085582 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-based intracoronary Q measurement
Number of subjects: 0
Study 12450711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrice (Sensodyne Baking Soda)
Number of subjects: 180
Study 12450711 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoride-containing dentifrice (Sensodyne Original)
Number of subjects: 180
Study 12450711 — intervention group
Group type: COMPARATOR
Intervention: Control group (Filtek Z250/3M)
Number of subjects: 180
Study 10358492 — intervention group
Group type: EXPERIMENTAL
Intervention: High likelihood of pain and difficult to console
Number of subjects: 48
Study 10358492 — intervention group
Group type: EXPERIMENTAL
Intervention: High likelihood of pain and easily consoled
Number of subjects: 48
Study 10358492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low likelihood of pain and difficult to console
Number of subjects: 48
Study 10358492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low likelihood of pain and easily consoled
Number of subjects: 48
Study 7864267 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-night sleep deprivation (3:00 a.m. to 7:00 a.m.) followed by recovery sleep (11:00 p.m. to 7:00 a.m.)
Number of subjects: 41
Study 7864267 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night sleep deprivation (9:00 p.m. to 1:00 a.m.) followed by recovery sleep
Number of subjects: 41
Study 7864267 — intervention group
Group type: COMPARATOR
Intervention: Early-night sleep deprivation
Number of subjects: 41
Study 7864267 — intervention group
Group type: COMPARATOR
Intervention: Late-night sleep deprivation
Number of subjects: 41
Study 2285584 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microgram ethinylestradiol (EE2)
Number of subjects: 165
Study 2285584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 165
Study 7029758 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-plasty
Number of subjects: 0
Study 7029758 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage or marsupialization (Control)
Number of subjects: 0
Study 31884320 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 173
Study 31488119 — intervention group
Group type: COMPARATOR
Intervention: Medical debriefing
Number of subjects: 0
Study 31488119 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamGAINS debriefing
Number of subjects: 0
Study 28926095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment
Number of subjects: 7145
Study 28926095 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical test product (20% change in AUC)
Number of subjects: 7145
Study 25855325 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) 75 IU
Number of subjects: 219
Study 25855325 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg
Number of subjects: 219
Study 23296694 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 5 mg/kg in two daily doses for 60 days (Group A)
Number of subjects: 124
Study 23296694 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole 7.5 mg/kg in a single daily dose for 30 days (Group B)
Number of subjects: 124
Study 23296694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens of benznidazole
Number of subjects: 124
Study 21362162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroquine (400 to 1,600 mg single dose; up to 800 mg repeated dose)
Number of subjects: 66
Study 21362162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19906346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 788
Study 19906346 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 788
Study 19906346 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 788
Study 16475604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (Sensodyne Original Formula) with restorative materials
Number of subjects: 240
Study 16475604 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoridated dentifrice (Sensodyne Sodium Bicarbonate) with restorative materials
Number of subjects: 240
Study 16475604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Fil with fluoridated dentifrice
Number of subjects: 240
Study 16475604 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement with dentifrices
Number of subjects: 240
Study 12087932 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (EP)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: COMPARATOR
Intervention: Regular verbal counselling (VC)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch subgroup (EP)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: COMPARATOR
Intervention: Patch subgroup (VC)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel subgroup (EP)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: COMPARATOR
Intervention: Gel subgroup (VC)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: COMPARATOR
Intervention: Continuous HRT regimen (VC)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: COMPARATOR
Intervention: Sequential HRT regimen (VC)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HRT regimen (EP)
Number of subjects: 1192
Study 12087932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential HRT regimen (EP)
Number of subjects: 1192
Study 10566550 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 652
Study 10566550 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 652
Study 10566550 — intervention group
Group type: COMPARATOR
Intervention: GSTM1 null genotype
Number of subjects: 652
Study 8722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed local anesthetic (40 degrees C)
Number of subjects: 26
Study 8722977 — intervention group
Group type: COMPARATOR
Intervention: Room temperature local anesthetic (21 degrees C)
Number of subjects: 26
Study 2014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus Is‐5‐Mn (40 mg twice a day)
Number of subjects: 50
Study 2014947 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 50
Study 2014947 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 50
Study 2014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus Is‐5‐Mn
Number of subjects: 50
Study 2014947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Propranolol plus Is‐5‐Mn
Number of subjects: 50
Study 6185788 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxalol (100-400 mg twice daily)
Number of subjects: 29
Study 6185788 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxalol + Hydrochlorothiazide (12.5 mg twice daily)
Number of subjects: 29
Study 6185788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after medroxalol withdrawal)
Number of subjects: 29
Study 30907001 — intervention group
Group type: COMPARATOR
Intervention: 23‐valent pneumococcal polysaccharide vaccine (23vPPV)
Number of subjects: 4725
Study 30907001 — intervention group
Group type: COMPARATOR
Intervention: Facebook advertising and snowball sampling
Number of subjects: 4725
Study 28107276 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB (rocuronium bolus and infusion maintaining a posttetanic count of 1‐2)
Number of subjects: 60
Study 28107276 — intervention group
Group type: COMPARATOR
Intervention: Moderate NMB (rocuronium bolus and top‐ups maintaining a train‐of‐four count of 1‐2)
Number of subjects: 60
Study 28107276 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 60
Study 28107276 — intervention group
Group type: COMPARATOR
Intervention: Moderate NMB
Number of subjects: 60
Study 26253567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25-50 mg
Number of subjects: 486
Study 26253567 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10-20 mg
Number of subjects: 486
Study 26253567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and amiloride at half doses
Number of subjects: 486
Study 26253567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during single-blind run-in)
Number of subjects: 486
Study 23599119 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic B. infantis (4.2 × 10(9) colony‐forming units two times daily)
Number of subjects: 16
Study 23599119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23599119 — intervention group
Group type: COMPARATOR
Intervention: Healthy control infants (N=6)
Number of subjects: 16
Study 21306798 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen room
Number of subjects: 0
Study 21306798 — intervention group
Group type: COMPARATOR
Intervention: Garden condition
Number of subjects: 0
Study 19666658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate powder
Number of subjects: 31
Study 19666658 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride tablets
Number of subjects: 31
Study 18051724 — intervention group
Group type: EXPERIMENTAL
Intervention: Upsher‐scope (USSP)
Number of subjects: 50
Study 18051724 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 50
Study 18051724 — intervention group
Group type: COMPARATOR
Intervention: Both USSP and MDLS
Number of subjects: 50
Study 16052334 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) measurements in patients with TSC
Number of subjects: 4
Study 16052334 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 4
Study 11985388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg daily
Number of subjects: 53
Study 11985388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10330635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% jelly applied once on arrival at the surgicenter
Number of subjects: 180
Study 10330635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% jelly applied on arrival and about 5 minutes prior to surgery
Number of subjects: 180
Study 10330635 — intervention group
Group type: COMPARATOR
Intervention: Topical eyedrop anesthesia
Number of subjects: 180
Study 10330635 — intervention group
Group type: COMPARATOR
Intervention: Intracameral lidocaine
Number of subjects: 180
Study 8545141 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream (0.075%) applied 4 times a day
Number of subjects: 40
Study 8545141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl nicotinate) applied 4 times a day
Number of subjects: 40
Study 1901528 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg b.i.d.
Number of subjects: 34
Study 1901528 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg t.i.d.
Number of subjects: 34
Study 1901528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6280052 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 188
Study 6280052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol ointment)
Number of subjects: 188
Study 31717948 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder supplementation for up to 3 months
Number of subjects: 224
Study 29231321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion periodic therapy
Number of subjects: 60
Study 29231321 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture-moxibustion therapy
Number of subjects: 60
Study 26212400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Intensity of Therapy Scale
Number of subjects: 1946
Study 26212400 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed‐effects modeling
Number of subjects: 1946
Study 22371090 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.7 ppm for 4 hours
Number of subjects: 41
Study 22371090 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.4 ppm for 4 hours with peaks of 0.8 ppm for 15 minutes
Number of subjects: 41
Study 22371090 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective complaints regarding olfactory symptoms
Number of subjects: 41
Study 22371090 — intervention group
Group type: COMPARATOR
Intervention: Control condition (0 ppm)
Number of subjects: 41
Study 20947648 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 24
Study 20947648 — intervention group
Group type: COMPARATOR
Intervention: room air
Number of subjects: 24
Study 19060263 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medicine or surgery
Number of subjects: 607
Study 19060263 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers with moderate/severe bilateral visual field loss (VFL)
Number of subjects: 607
Study 19060263 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers who remained drivers over follow-up
Number of subjects: 607
Study 16856702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration board training (25 hertz, 10 repetitions lasting 1 minute each, for 2 weeks)
Number of subjects: 16
Study 16856702 — intervention group
Group type: COMPARATOR
Intervention: Control group training (10 daily sessions for 2 weeks, 3 series of 10 repetitions of flexi‐extension of the foot against an elastic band)
Number of subjects: 16
Study 12883361 — intervention group
Group type: COMPARATOR
Intervention: 5‐S‐Cysteinyldopa (5‐S‐CD)
Number of subjects: 152
Study 12883361 — intervention group
Group type: COMPARATOR
Intervention: 4‐Amino‐3‐hydroxyphenylalanine (4‐AHP)
Number of subjects: 152
Study 12883361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum levels
Number of subjects: 152
Study 12883361 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 4‐AHP levels
Number of subjects: 152
Study 10834891 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax
Number of subjects: 1442
Study 10834891 — intervention group
Group type: COMPARATOR
Intervention: Phosphate enema
Number of subjects: 1442
Study 9337827 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive assist-control ventilation (ACV)
Number of subjects: 15
Study 9337827 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 15
Study 7692410 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic 6500
Number of subjects: 35
Study 7692410 — intervention group
Group type: COMPARATOR
Intervention: Braided multifilament temporary pacing leads
Number of subjects: 35
Study 3754433 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace worn for 6 weeks
Number of subjects: 17